NLRP3 and acute lymphoblastic leukemia: The dysregulation of the inflammasome complex can also influence the prognosis of patients, since studies report that the constitutive activation of NLRP3 seems to cleave the glucocorticoid receptor, this being the first line of treatment for ALL, and thus increase the number of relapses9,10.